microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1312-1320

  Wang, Chengde ^a   Su, Zhipeng ^a   Sanai, Nader ^b   Xue, Xiangyang ^a   Lu, Lijun ^a   Chen, Yunxiang ^a   Wu, Jinsen ^a   Zheng, Weiming ^a   Zhuge, Qichuan ^a   Wu, Zhe Bao ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Bromocriptine; Microarray; microRNAs; PDGFA; Prolactinoma

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; BROMOCRIPTINE; MICRORNA; PLATELET DERIVED GROWTH FACTOR A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MICROSURGERY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROLACTINOMA; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; ANTINEOPLASTIC AGENTS; BROMOCRIPTINE; CLUSTER ANALYSIS; DOPAMINE AGONISTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; YOUNG ADULT;

EID: 84863260561     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1690     Document Type: Article

References (40)

1. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS and Zheng WM: Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104: 54-61, 2006.
2. Stefaneanu L, Kovacs K, Scheithauer BW, et al: Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 11: 341-352, 2000. (Pubitemid 32436869)
3. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R and Borrelli E: Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci USA 99: 14530-14535, 2002. (Pubitemid 35257705)
4. Paez-Pereda M, Giacomini D, Echenique C, Stalla GK, Holsboer F and Arzt E: Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs. Curr Drug Targets Immune Endocr Metabol Disord 5: 259-267, 2005. (Pubitemid 41131705)
5. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS and Baik JH: Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206: 49-62, 2003. (Pubitemid 37011252)
6. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
7. Kanellopoulou C, Muljo SA, Kung AL, et al: Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev 19: 489-501, 2005. (Pubitemid 40256280)
8. Croce CM and Calin GA: miRNAs, cancer and stem cell division. Cell 122: 6-7, 2005. (Pubitemid 40977933)
9. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
10. Bak M, Silahtaroglu A, Moller M, et al: MicroRNA expression in the adult mouse central nervous system. RNA 14: 432-444, 2008. (Pubitemid 351397808)
11. Farh KK, Grimson A, Jan C, et al: The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 310: 1817-1821, 2005. (Pubitemid 41814382)
12. Landgraf P, Rusu M, Sheridan R, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414, 2007. (Pubitemid 46970709)
13. Zhang Z, Florez S, Gutierrez-Hartmann A, Martin JF and Amendt BA: MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression. J Biol Chem 285: 34718-34728, 2010.
14. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC and degli Uberti EC: miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol 204: 280-285, 2005. (Pubitemid 40776831)
15. Bottoni A, Zatelli MC, Ferracin M, et al: Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol 210: 370-377, 2007. (Pubitemid 44956882)
16. Zatelli MC and degli Uberti EC: microRNAs and possible role in pituitary adenoma. Semin Reprod Med 26: 453-460, 2008.
17. Amaral FC, Torres N, Saggioro F, et al: microRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab 94: 320-323, 2009.
18. Qian ZR, Asa SL, Siomi H, et al: Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 22: 431-441, 2009.
19. Butz H, Liko I, Czirjak S, et al: microRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary 14: 112-124, 2011.
20. Butz H, Liko I, Czirjak S, et al: Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab 95: E181-E191, 2010.
21. Stilling G, Sun Z, Zhang S, et al: microRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 38: 67-75, 2010.
22. Wu ZB, Zheng WM, Su ZP, et al: Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol 99: 25-32, 2010.
23. Xue X, Sun J, Zhang Q, Wang Z, Huang Y and Pan W: Identification and characterization of novel microRNAs from Schistosoma japonicum. PLoS One 3: e4034, 2008.
24. Sterrenburg E, Turk R, Boer JM, van Ommen GB and den Dunnen JT: A common reference for cDNA microarray hybridizations. Nucleic Acids Res 30: e116, 2002.
25. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
26. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
28. Gruszka A, Kunert-Radek J and Pawlikowski M: The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma: the effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma. Folia Histochem Cytobiol 42: 35-39, 2004.
29. Song G, Zhang Y and Wang L: microRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 284: 31921-31927, 2009.
30. Yan D, Dong Xda E, Chen X, et al: microRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284: 29596-29604, 2009.
31. Missiaglia E, Shepherd CJ, Patel S, et al: microRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 102: 1769-1777, 2010.
32. Lujambio A, Calin GA, Villanueva A, et al: A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105: 13556-13561, 2008.
33. Lerebours F, Tozlu-Kara S, Vacher S, Lidereau R and Bieche I: microRNA expression profiling of inflammatory breast cancer. Cancer Res 69: 2009.
34. Sullivan NJ and Tashjian AH Jr: Platelet-derived growth factor selectively decreases prolactin production in pituitary cells in culture. Endocrinology 113: 639-645, 1983. (Pubitemid 13048956)
35. MacDonald TJ, Brown KM, LaFleur B, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29: 143-152, 2001. (Pubitemid 32952650)
36. Grossman AB: The molecular biology of pituitary tumors: a personal perspective. Pituitary 12: 265-270, 2009.
37. Iwama H, Murao K, Imachi H and Ishida T: microRNA networks alter to conform to transcription factor networks adding redundancy and reducing the repertoire of target genes for coordinated regulation. Mol Biol Evol 28: 639-646, 2011.
38. Scully KM and Rosenfeld MG: Pituitary development: regulatory codes in mammalian organogenesis. Science 295: 2231-2235, 2002. (Pubitemid 34258830)
39. Paez-Pereda M, Giacomini D, Refojo D, et al: Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 100: 1034-1039, 2003. (Pubitemid 36183950)
40. Miyoshi T, Otsuka F, Otani H, et al: Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells. J Endocrinol 197: 159-169, 2008. (Pubitemid 351566935)